MedTrace Logo

Use of a Liquid Biopsy Signature to Detect Early-onset Gastric Cancer

NCT06023121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2023-09-05

No results posted yet for this study

Summary

Early-onset gastric cancer (EOGC) is a lethal malignancy with a poor prognosis. It differs from late-onset gastric cancer (LOGC) in clinical and molecular characteristics. The current strategies for EOGC detection have certain limitations in diagnostic performance due to the rising trend in EOGC. Hence, identifying novel EOGC bioindicators is crucial.

Conditions

Interventions

DIAGNOSTIC_TEST

Measurement of levels of an exosome-based liquid biopsy signature

Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-08-01
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06023121 on ClinicalTrials.gov